Meeder Asset Management Inc. Lowers Holdings in Catalent Inc (CTLT)
Meeder Asset Management Inc. trimmed its stake in Catalent Inc (NYSE:CTLT) by 15.1% in the 3rd quarter, HoldingsChannel.com reports. The institutional investor owned 17,118 shares of the company’s stock after selling 3,048 shares during the period. Meeder Asset Management Inc.’s holdings in Catalent were worth $780,000 at the end of the most recent quarter.
Other institutional investors also recently added to or reduced their stakes in the company. Nelson Van Denburg & Campbell Wealth Management Group LLC purchased a new stake in Catalent in the 2nd quarter valued at about $145,000. Moneta Group Investment Advisors LLC boosted its position in Catalent by 105.0% in the 2nd quarter. Moneta Group Investment Advisors LLC now owns 3,515 shares of the company’s stock valued at $147,000 after buying an additional 1,800 shares during the period. Hartford Investment Management Co. bought a new stake in shares of Catalent in the 2nd quarter valued at about $220,000. Rehmann Capital Advisory Group raised its holdings in shares of Catalent by 1,895.9% in the 2nd quarter. Rehmann Capital Advisory Group now owns 5,309 shares of the company’s stock valued at $222,000 after purchasing an additional 5,043 shares in the last quarter. Finally, Chicago Equity Partners LLC bought a new stake in shares of Catalent in the 3rd quarter valued at about $237,000. 92.08% of the stock is owned by institutional investors.
NYSE:CTLT opened at $37.51 on Friday. Catalent Inc has a one year low of $34.24 and a one year high of $47.87. The company has a debt-to-equity ratio of 1.44, a current ratio of 2.05 and a quick ratio of 1.79. The stock has a market capitalization of $5.48 billion, a PE ratio of 22.99, a price-to-earnings-growth ratio of 2.24 and a beta of 1.45.
Several equities research analysts have recently commented on the stock. TheStreet lowered shares of Catalent from a “b-” rating to a “c+” rating in a report on Wednesday. Royal Bank of Canada set a $44.00 price target on shares of Catalent and gave the company a “buy” rating in a report on Wednesday. First Analysis upgraded shares of Catalent from a “neutral” rating to an “outperform” rating and reduced their price target for the company from $47.00 to $43.00 in a report on Wednesday. ValuEngine lowered shares of Catalent from a “buy” rating to a “hold” rating in a report on Tuesday. Finally, Zacks Investment Research upgraded shares of Catalent from a “sell” rating to a “hold” rating in a report on Tuesday, October 30th. Five research analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. Catalent presently has an average rating of “Buy” and an average target price of $48.11.
In related news, SVP Lance Miyamoto sold 6,525 shares of the business’s stock in a transaction that occurred on Tuesday, October 16th. The shares were sold at an average price of $42.50, for a total transaction of $277,312.50. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Donald E. Morel, Jr. acquired 10,000 shares of Catalent stock in a transaction that occurred on Thursday, September 13th. The shares were purchased at an average price of $43.00 per share, with a total value of $430,000.00. The disclosure for this purchase can be found here. In the last quarter, insiders have sold 184,335 shares of company stock valued at $8,161,727. 1.40% of the stock is currently owned by company insiders.
TRADEMARK VIOLATION WARNING: “Meeder Asset Management Inc. Lowers Holdings in Catalent Inc (CTLT)” was first posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this article on another website, it was stolen and reposted in violation of U.S. and international copyright & trademark legislation. The legal version of this article can be accessed at https://www.thecerbatgem.com/2018/11/10/meeder-asset-management-inc-lowers-holdings-in-catalent-inc-ctlt.html.
Catalent Company Profile
Catalent, Inc provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products worldwide. It operates through four segments: Softgel Technologies, Biologics and Specialty Drug Delivery, Oral Drug Delivery, and Clinical Supply Services. The Softgel Technologies segment formulates, develops, and manufactures prescription and consumer soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations.
Featured Article: Day Trading
Want to see what other hedge funds are holding CTLT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Catalent Inc (NYSE:CTLT).
Receive News & Ratings for Catalent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent and related companies with MarketBeat.com's FREE daily email newsletter.